Published in Proc Natl Acad Sci U S A on May 21, 2007
Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol Neurodegener (2013) 1.35
Alzheimer's disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis (2012) 1.31
Immunotherapeutic approaches for Alzheimer's disease. Neuron (2015) 1.13
Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets? Immun Ageing (2013) 1.08
Immunotherapy for Alzheimer's disease. Biochem Pharmacol (2014) 1.04
Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention. CNS Neurol Disord Drug Targets (2010) 1.02
Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. PLoS One (2013) 1.00
Tau aggregation and its interplay with amyloid-β. Acta Neuropathol (2014) 0.93
Immunotherapy for tauopathies. J Mol Neurosci (2011) 0.92
Developing therapeutic vaccines against Alzheimer's disease. Expert Rev Vaccines (2015) 0.90
Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders. Neurotherapeutics (2016) 0.90
CD4 T cells in immunity and immunotherapy of Alzheimer's disease. Immunology (2013) 0.89
A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease. Alzheimers Dement (2015) 0.89
Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease). J Drug Deliv (2011) 0.88
Advances in Alzheimer's disease drug development. BMC Med (2015) 0.88
Extracellular vesicles and their synthetic analogues in aging and age-associated brain diseases. Biogerontology (2014) 0.87
Sequence-independent control of peptide conformation in liposomal vaccines for targeting protein misfolding diseases. J Biol Chem (2011) 0.86
Co-immunization with DNA and protein mixture: a safe and efficacious immunotherapeutic strategy for Alzheimer's disease in PDAPP mice. Sci Rep (2015) 0.84
Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds. Neurobiol Aging (2013) 0.84
Active immunotherapy options for Alzheimer's disease. Alzheimers Res Ther (2014) 0.83
Immunocytochemical characterization of Alzheimer disease hallmarks in APP/PS1 transgenic mice treated with a new anti-amyloid-β vaccine. Biomed Res Int (2013) 0.83
Vaccine Development to Treat Alzheimer's Disease Neuropathology in APP/PS1 Transgenic Mice. Int J Alzheimers Dis (2012) 0.82
The antigenic repertoire of premalignant and high-risk lesions. Cancer Prev Res (Phila) (2015) 0.81
Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges. Mol Neurodegener (2016) 0.80
Current Research Therapeutic Strategies for Alzheimer's Disease Treatment. Neural Plast (2016) 0.80
Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease. Neurobiol Dis (2010) 0.78
Interaction between therapeutic interventions for Alzheimer's disease and physiological Aβ clearance mechanisms. Front Aging Neurosci (2015) 0.78
An Anti-β-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome. PLoS One (2016) 0.77
Tailoring the antibody response to aggregated Aß using novel Alzheimer-vaccines. PLoS One (2015) 0.76
Advances in recent patent and clinical trial drug development for Alzheimer's disease. Pharm Pat Anal (2014) 0.76
Amyloid-beta immunotherapy: the hope for Alzheimer disease? Colomb Med (Cali) (2016) 0.75
Novel immunological approaches for the treatment of Alzheimer's disease. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi (2014) 0.75
Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope. J Alzheimers Dis (2016) 0.75
Overexpression of Swedish mutant APP in aged astrocytes attenuates excitatory synaptic transmission. Physiol Rep (2016) 0.75
Biomaterials for the Treatment of Alzheimer's Disease. Front Bioeng Biotechnol (2016) 0.75
Potential sources of interference on Abeta immunoassays in biological samples. Alzheimers Res Ther (2012) 0.75
Rafts, Nanoparticles and Neural Disease. Nanomaterials (Basel) (2012) 0.75
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science (1996) 19.72
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95
Estimation of protein secondary structure from circular dichroism spectra: comparison of CONTIN, SELCON, and CDSSTR methods with an expanded reference set. Anal Biochem (2000) 11.10
A structural model for Alzheimer's beta -amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci U S A (2002) 9.55
Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med (2000) 8.89
Genetic enhancement of learning and memory in mice. Nature (1999) 8.06
Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med (2003) 7.83
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2001) 7.35
Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology (2003) 6.51
Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 5.60
Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci (2002) 5.01
Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron (2004) 4.88
Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta (1991) 4.16
Enrichment induces structural changes and recovery from nonspatial memory deficits in CA1 NMDAR1-knockout mice. Nat Neurosci (2000) 4.01
Staging of Alzheimer-related cortical destruction. Eur Neurol (1993) 3.58
Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem (1999) 3.20
Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol (2004) 3.01
Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem (2005) 2.47
Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol (2006) 2.33
Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol (2000) 2.30
Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci (1993) 2.12
Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest (2005) 1.96
Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch Neurol (2004) 1.78
Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest (2003) 1.59
Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J Neurosci (2006) 1.51
Identification of the mouse IgG3 receptor: implications for antibody effector function at the interface between innate and adaptive immunity. J Immunol (1998) 1.45
An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J Neurosci (2004) 1.43
Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 1.41
Structural changes of region 1-16 of the Alzheimer disease amyloid beta-peptide upon zinc binding and in vitro aging. J Biol Chem (2005) 1.40
Conformational polymorphism of the amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. J Biol Chem (1994) 1.07
Abeta42 gene vaccination reduces brain amyloid plaque burden in transgenic mice. J Neurol Sci (2006) 1.05
Aging increased amyloid peptide and caused amyloid plaques in brain of old APP/V717I transgenic mice by a different mechanism than mutant presenilin1. J Neurosci (2000) 1.04
Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice. Neurobiol Aging (2006) 1.01
The alignment, structure and dynamics of membrane-associated polypeptides by solid-state NMR spectroscopy. Biochim Biophys Acta (2004) 1.01
Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease. Mol Med Today (1999) 0.99
Non-covalent stabilization of a beta-hairpin peptide into liposomes. Org Biomol Chem (2003) 0.86
A liposome-based therapeutic vaccine against beta -amyloid plaques on the pancreas of transgenic NORBA mice. Proc Natl Acad Sci U S A (2002) 0.85
Immune response against the murine mdri protein induced by vaccination with synthetic lipopeptides in liposomes. Biochem Biophys Res Commun (1995) 0.83
Design and synthesis of basic peptides having amphipathic beta-structure and their interaction with phospholipid membranes. Biochim Biophys Acta (1990) 0.80
AD neuropathology. Neurology (1996) 0.79
Evidence of secondary structure by high-resolution magic angle spinning NMR spectroscopy of a bioactive peptide bound to different solid supports. J Am Chem Soc (2001) 0.78
Multilamellar liposomes formed by phosphatidyl nucleosides: an NMR-HR-MAS characterization. Langmuir (2004) 0.77
Synthetic mammalian prions. Science (2004) 7.35
Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A (2008) 2.87
A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest (2004) 2.52
Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) (2002) 2.51
APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood (2008) 2.44
Prion detection by an amyloid seeding assay. Proc Natl Acad Sci U S A (2007) 2.34
Fabry disease in childhood. J Pediatr (2004) 2.20
Lysosomal alpha-galactosidase controls the generation of self lipid antigens for natural killer T cells. Immunity (2010) 2.09
Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant (2005) 1.84
Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A (2006) 1.81
Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol (2007) 1.59
Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis. Proc Natl Acad Sci U S A (2003) 1.57
Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci (2003) 1.56
The capsaicin receptor TRPV1 is a crucial mediator of the noxious effects of mustard oil. Curr Biol (2011) 1.56
Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve (2003) 1.51
Skin-impedance in Fabry Disease: a prospective, controlled, non-randomized clinical study. BMC Neurol (2008) 1.51
Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note. J Neurosurg (2007) 1.51
Search for a prion-specific nucleic acid. J Virol (2005) 1.44
Mechanisms of prion protein assembly into amyloid. Proc Natl Acad Sci U S A (2008) 1.43
Pediatric Fabry disease. Pediatrics (2005) 1.43
Improved long-term potentiation and memory in young tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy. J Neurosci (2006) 1.41
An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci (2012) 1.36
Cyclin-dependent kinase 5 activity regulates pain signaling. Proc Natl Acad Sci U S A (2006) 1.34
Cyclin-dependent kinase 5 modulates nociceptive signaling through direct phosphorylation of transient receptor potential vanilloid 1. Proc Natl Acad Sci U S A (2006) 1.31
Abeta42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Abeta42 species. J Biol Chem (2010) 1.28
New prospects for the treatment of lysosomal storage diseases. Drugs (2002) 1.26
Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. Proc Natl Acad Sci U S A (2004) 1.25
Effective cell and gene therapy in a murine model of Gaucher disease. Proc Natl Acad Sci U S A (2006) 1.25
Murine models of acute neuronopathic Gaucher disease. Proc Natl Acad Sci U S A (2007) 1.23
Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine (2004) 1.23
Transfer of a mitochondrial DNA fragment to MCOLN1 causes an inherited case of mucolipidosis IV. Hum Mutat (2004) 1.22
Increased activity of cyclin-dependent kinase 5 leads to attenuation of cocaine-mediated dopamine signaling. Proc Natl Acad Sci U S A (2005) 1.21
Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics (2006) 1.20
Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies. J Neurosci (2010) 1.20
Investigations of polypeptide rotational diffusion in aligned membranes by 2H and 15N solid-state NMR spectroscopy. J Am Chem Soc (2004) 1.19
Rho-kinase: regulation, (dys)function, and inhibition. Biol Chem (2013) 1.17
A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease. Haematologica (2008) 1.16
Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function. Proc Natl Acad Sci U S A (2011) 1.13
Histidine-rich amphipathic peptide antibiotics promote efficient delivery of DNA into mammalian cells. Proc Natl Acad Sci U S A (2003) 1.13
Assembly of natural and recombinant prion protein into fibrils. Biol Chem (2005) 1.13
Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study. J Magn Reson Imaging (2004) 1.12
Screening for pharmacological chaperones in Fabry disease. Biochem Biophys Res Commun (2007) 1.11
A novel low-E field coil to minimize heating of biological samples in solid-state multinuclear NMR experiments. J Magn Reson (2007) 1.10
Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke (2002) 1.10
Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl. Proc Natl Acad Sci U S A (2010) 1.09
Convection perfusion of glucocerebrosidase for neuronopathic Gaucher's disease. Ann Neurol (2005) 1.08
Design and evaluation of histidine-rich amphipathic peptides for siRNA delivery. Pharm Res (2010) 1.08
Probiotics and immune response. Clin Rev Allergy Immunol (2002) 1.07
Cationic amphipathic histidine-rich peptides for gene delivery. Biochim Biophys Acta (2006) 1.07
Determinants of structural and functional plasticity of a widely conserved protease chaperone complex. Nat Struct Mol Biol (2010) 1.07
Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease. Proc Natl Acad Sci U S A (2011) 1.06
Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone. Pharmacogenet Genomics (2008) 1.06
Structural determinants of antimicrobial and antiplasmodial activity and selectivity in histidine-rich amphipathic cationic peptides. J Biol Chem (2008) 1.06
Loss of gamma-secretase function impairs endocytosis of lipoprotein particles and membrane cholesterol homeostasis. J Neurosci (2008) 1.05
Reduction of Alzheimer's disease amyloid plaque load in transgenic mice by D3, A D-enantiomeric peptide identified by mirror image phage display. ChemMedChem (2008) 1.04
Predominant influence of environmental determinants on the persistence and avidity maturation of antibody responses to vaccines in infants. J Infect Dis (2006) 1.04
Gene transfer into the central nervous system in vivo using a recombinanat lentivirus vector. J Neurosci Res (2002) 1.03
A yeast-based model of alpha-synucleinopathy identifies compounds with therapeutic potential. Biochim Biophys Acta (2005) 1.03
Fabry disease and vascular risk factors: future strategies for patient-based studies and the knockout murine model. Acta Paediatr Suppl (2006) 1.01
Structure and topology of the huntingtin 1-17 membrane anchor by a combined solution and solid-state NMR approach. Biophys J (2013) 1.01
Detection of prion particles in samples of BSE and scrapie by fluorescence correlation spectroscopy without proteinase K digestion. Biol Chem (2006) 1.00
Lack of susceptibility of cells from patients with Fabry disease to productive infection with R5 human immunodeficiency virus. AIDS (2005) 1.00
Structure and dynamics of membrane-associated ICP47, a viral inhibitor of the MHC I antigen-processing machinery. J Biol Chem (2006) 1.00
Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. PLoS One (2013) 1.00
Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice. FASEB J (2011) 1.00
Perinatal abrogation of Cdk5 expression in brain results in neuronal migration defects. Proc Natl Acad Sci U S A (2004) 1.00
Inhibition of B cell death causes the development of an IgA nephropathy in (New Zealand white x C57BL/6)F(1)-bcl-2 transgenic mice. J Immunol (2004) 1.00
Calcium ions promote formation of amyloid β-peptide (1-40) oligomers causally implicated in neuronal toxicity of Alzheimer's disease. PLoS One (2011) 1.00
The antibiotic and DNA-transfecting peptide LAH4 selectively associates with, and disorders, anionic lipids in mixed membranes. FASEB J (2005) 0.99
Zwitterionic phospholipids and sterols modulate antimicrobial peptide-induced membrane destabilization. Biophys J (2007) 0.99
Oral treatment with the d-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer's Disease transgenic mice. ACS Chem Neurosci (2010) 0.98
Lipid-controlled peptide topology and interactions in bilayers: structural insights into the synergistic enhancement of the antimicrobial activities of PGLa and magainin 2. Biophys J (2011) 0.98
Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer. Proc Natl Acad Sci U S A (2003) 0.97
Structure and alignment of the membrane-associated peptaibols ampullosporin A and alamethicin by oriented 15N and 31P solid-state NMR spectroscopy. Biophys J (2009) 0.97
Solid-state NMR spectroscopy of oriented membrane polypeptides at 100 K with signal enhancement by dynamic nuclear polarization. J Am Chem Soc (2010) 0.97
The N370S (Asn370-->Ser) mutation affects the capacity of glucosylceramidase to interact with anionic phospholipid-containing membranes and saposin C. Biochem J (2005) 0.96
TLR4- and TRIF-dependent stimulation of B lymphocytes by peptide liposomes enables T cell-independent isotype switch in mice. Blood (2012) 0.96
Macromolecular crowding at membrane interfaces: adsorption and alignment of membrane peptides. J Mol Biol (2007) 0.96
Enzyme replacement therapy and intraepidermal innervation density in Fabry disease. Muscle Nerve (2006) 0.96
Structural changes of membrane-anchored native PrP(C). Proc Natl Acad Sci U S A (2008) 0.96
Enhanced exercise capacity in mice with severe heart failure treated with an allosteric effector of hemoglobin, myo-inositol trispyrophosphate. Proc Natl Acad Sci U S A (2009) 0.96
β-Catenin signaling initiates the activation of astrocytes and its dysregulation contributes to the pathogenesis of astrocytomas. Proc Natl Acad Sci U S A (2012) 0.96
Detection of prion protein particles in blood plasma of scrapie infected sheep. PLoS One (2012) 0.96
Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones. Proc Natl Acad Sci U S A (2012) 0.95
A novel, enzymatically active conformation of the Escherichia coli NADH:ubiquinone oxidoreductase (complex I). J Biol Chem (2002) 0.95
Conditional deletion of neuronal cyclin-dependent kinase 5 in developing forebrain results in microglial activation and neurodegeneration. Am J Pathol (2009) 0.95
Deciphering membrane insertion of the diphtheria toxin T domain by specular neutron reflectometry and solid-state NMR spectroscopy. J Mol Biol (2009) 0.95
Double-strand DNA end-binding and sliding of the toroidal CRISPR-associated protein Csn2. Nucleic Acids Res (2013) 0.95
A validated disease severity scoring system for Fabry disease. Mol Genet Metab (2009) 0.95
Accumulation of viroid-specific small RNAs and increase in nucleolytic activities linked to viroid-caused pathogenesis. Biol Chem (2007) 0.95